PCVX

Vaxcyte Inc. (PCVX) | Rumor.io

Vaxcyte

PCVX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,550

Bullish sentiment (50-day avg)42%

Price to earnings ratio-10.3

Market capitalization8.7B

Earnings per share-7.63

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-766.6M

Social

What share of all stock conversation is about PCVX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jun 6

Vaxcyte, Inc. (PCVX) is mentioned alongside other stocks in a list of daily long ideas.
The post does not provide any specific information about PCVX or Vaxcyte, Inc.
No market-relevant information is available from this post.

Generated by AI

Sentiment

Of the messages about PCVX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.11% +36.55
Bearish	—	—	—	21.89% -36.55

Bullish· Jun 6

Vaxcyte, Inc. ($PCVX) is a top daily long idea, indicating strong potential for growth.
The company's innovative approach is preferred over complex algorithms, highlighting its unique value proposition.
$PCVX is a bright spot in a diversified portfolio, with a high potential for returns.

Bearish· Mar 31

Vaxcyte, Inc. (PCVX) has dropped 60% in less than 6 months after raising $1.2 billion at $103.
The company's Phase 3 program initiation has been delayed until mid-2026 pending VAX-31 results, and it did not meet non-inferiority criteria for all 24 serotypes.
PCVX has fallen 52% after releasing phase 2 data, with some investors viewing the drop as an overreaction.

Generated by AI

Topics

Of the messages about PCVX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	90.91%	94.44%	71.63%
Analysts	—	9.09%	5.56%	14.18%
Technical Analysis	—	0%	0%	8.65%
Controversies	—	0%	0%	4.81%
Earnings	—	0%	0%	0.72%
Macro	—	0%	0%	0%

Mar 31

Vaxcyte, Inc. (PCVX) announced positive topline results from its VAX-24 infant Phase 2 dose-finding study, with the Mid dose meeting non-inferiority criteria on relative seroconversion rates for 20 of 24 serotypes.
The study found that VAX-24 was well-tolerated, with a safety profile similar to Prevnar 20, and elicited substantial immunoglobulin G and opsonophagocytic assay immune responses at 1-month post-dose 3.
Vaxcyte plans to initiate an infant Phase 3 study with either VAX-24 or VAX-31, pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026.

Generated by AI

Community

Of the messages about PCVX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	11.11%	12.77%	21.79%	35.34%
Newcomers	88.89%	87.23%	78.21%	64.66%

Regulars· Jan 31

Vaxcyte, Inc. has priced a $750M public offering, with $PCVX trading 70.
Market participants believe $PCVX has a higher chance of success compared to Bbio, which may hurt PFE.
$PCVX is up 5.35% despite trading 252% above average volume, following the announcement of its public offering.

Newcomers· Apr 17

$PCVX's VAX-24 vaccine shows promise in older patients, potentially competing with $PFE's Prevnar 20.
The company's valuation is struggling, with some comparing it unfavorably to the Affinivax takeout price.
$PCVX has reported positive Phase 2 study results and six-month safety data for VAX-24 in adults aged 65 and older.

Generated by AI

News

BofA cuts Vaxcyte stock price target on launch timeline shift

2d agoInvesting.com

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.

6d agofinance.yahoo.com

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

Vaxcyte (PCVX) Dropped, So What Is Driving Attention Now?

8d agoYahoo Finance

Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears

On September 3, Vaxcyte (NASDAQ:PCVX) announced two new C-suite hires and moved up the date for its most important looming catalyst. The company said it now expects topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial by the end of October, narrowing guidance that had previously pointed only to sometime […]

13d agofinance.yahoo.com

Vaxcyte at Cantor conference: broad vaccine bet nears key test

20d agoInvesting.com

Also Discussed

Investors talking about PCVX also mention

#	Name	Attention
1	Sutro Biopharma Inc.STRO	0%new
2	Nuvalent, Inc.NUVL	0%0
3	DICE - DICE Therapeutics, Inc.	——
4	Biohaven Ltd.BHVN	0%-0.01
5	Rhythm Pharmaceuticals, Inc.RYTM	0%0
6	Autolus Therapeutics plc ADRAUTL	0%+0
7	Pharvaris N.V. Ordinary SharesPHVS	0%0
8	DAWN - Day One Biopharmaceuticals, Inc.	——
9	Pliant Therapeutics Inc.PLRX	0%0
10	Acumen Pharmaceuticals, Inc.ABOS	0%new

Vaxcyte Inc.

Healthcare
Biotechnology

Vaxcyte Inc. is a clinical-stage vaccine company focused on developing next-generation vaccines for bacterial infectious diseases. The company uses its proprietary cell-free protein synthesis platform to design and produce optimized protein carriers and antigens, supporting the creation of conjugate and protein-based vaccine candidates. Its current pipeline centers on pneumococcal programs aimed at preventing invasive pneumococcal disease, along with additional candidates targeting other serious bacterial conditions. Vaxcyte Inc. operates in the biotechnology and infectious disease markets, where its work addresses areas with significant unmet medical need. Based in San Carlos, California, the company is known for its emphasis on broad-spectrum vaccine design and advanced manufacturing methods that differ from conventional cell-based approaches.

Website

Location

825 Industrial Road

San Carlos, CA, 94070

United States

Social

What share of all stock conversation is about PCVX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jun 6

Vaxcyte, Inc. (PCVX) is mentioned alongside other stocks in a list of daily long ideas.
The post does not provide any specific information about PCVX or Vaxcyte, Inc.
No market-relevant information is available from this post.

Generated by AI

Sentiment

Of the messages about PCVX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.11% +36.55
Bearish	—	—	—	21.89% -36.55

Bullish· Jun 6

Vaxcyte, Inc. ($PCVX) is a top daily long idea, indicating strong potential for growth.
The company's innovative approach is preferred over complex algorithms, highlighting its unique value proposition.
$PCVX is a bright spot in a diversified portfolio, with a high potential for returns.

Bearish· Mar 31

Vaxcyte, Inc. (PCVX) has dropped 60% in less than 6 months after raising $1.2 billion at $103.
The company's Phase 3 program initiation has been delayed until mid-2026 pending VAX-31 results, and it did not meet non-inferiority criteria for all 24 serotypes.
PCVX has fallen 52% after releasing phase 2 data, with some investors viewing the drop as an overreaction.

Generated by AI

Topics

Of the messages about PCVX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	90.91%	94.44%	71.63%
Analysts	—	9.09%	5.56%	14.18%
Technical Analysis	—	0%	0%	8.65%
Controversies	—	0%	0%	4.81%
Earnings	—	0%	0%	0.72%
Macro	—	0%	0%	0%

Mar 31

Vaxcyte, Inc. (PCVX) announced positive topline results from its VAX-24 infant Phase 2 dose-finding study, with the Mid dose meeting non-inferiority criteria on relative seroconversion rates for 20 of 24 serotypes.
The study found that VAX-24 was well-tolerated, with a safety profile similar to Prevnar 20, and elicited substantial immunoglobulin G and opsonophagocytic assay immune responses at 1-month post-dose 3.
Vaxcyte plans to initiate an infant Phase 3 study with either VAX-24 or VAX-31, pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026.

Generated by AI

Community

Of the messages about PCVX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	11.11%	12.77%	21.79%	35.34%
Newcomers	88.89%	87.23%	78.21%	64.66%

Regulars· Jan 31

Vaxcyte, Inc. has priced a $750M public offering, with $PCVX trading 70.
Market participants believe $PCVX has a higher chance of success compared to Bbio, which may hurt PFE.
$PCVX is up 5.35% despite trading 252% above average volume, following the announcement of its public offering.

Newcomers· Apr 17

$PCVX's VAX-24 vaccine shows promise in older patients, potentially competing with $PFE's Prevnar 20.
The company's valuation is struggling, with some comparing it unfavorably to the Affinivax takeout price.
$PCVX has reported positive Phase 2 study results and six-month safety data for VAX-24 in adults aged 65 and older.

Generated by AI

Vaxcyte

Social

Jun 6

Bullish· Jun 6

Bearish· Mar 31

Mar 31

Regulars· Jan 31

Newcomers· Apr 17

BofA cuts Vaxcyte stock price target on launch timeline shift

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

Vaxcyte (PCVX) Dropped, So What Is Driving Attention Now?

Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears

Vaxcyte at Cantor conference: broad vaccine bet nears key test

Also Discussed

Vaxcyte Inc.

Company Information

Location

BofA cuts Vaxcyte stock price target on launch timeline shift

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

Vaxcyte (PCVX) Dropped, So What Is Driving Attention Now?

Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears

Vaxcyte at Cantor conference: broad vaccine bet nears key test

Also Discussed

Social

Jun 6

Bullish· Jun 6

Bearish· Mar 31

Mar 31

Regulars· Jan 31

Newcomers· Apr 17